<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2020.94039</article-id><article-id pub-id-type="publisher-id">HJO-39066</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20200400000_39930540.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  PET/CT影像新技术在青光眼诊断与评估方面的研究进展
  The Application Prospect of PET/CT in the Diagnosis and Evaluation of Glaucoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>任</surname><given-names>婉娜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>金瑞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>包</surname><given-names>宇涵</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>柳</surname><given-names>江燕</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>崔</surname><given-names>振存</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>兰大二院眼科，甘肃 兰州</addr-line></aff><aff id="aff3"><addr-line>甘肃省康复中心医院眼科，甘肃 兰州</addr-line></aff><aff id="aff4"><addr-line>兰大二院核医学科，甘肃 兰州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>20</day><month>10</month><year>2020</year></pub-date><volume>09</volume><issue>04</issue><fpage>274</fpage><lpage>279</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    近年来，人们对青光眼发病机制的了解不断加深，发现了阿尔茨海默病(AD)和青光眼在发病机制上有多种流行病学和组织学重叠。随着影像技术的不断发展，人们应用PET/CT诊断AD积累了一定的经验，用其研究青光眼的发病机制和作为青光眼的早期诊疗评估方法也在进行研究。然而，目前仍有很多问题需要明晰和探索。本文主要对此无创的影像检查在青光眼的诊疗方面的应用进展进行综述。
    With the development of understanding of the pathogenesis of glaucoma, we find that Alzheimer’s disease (AD) and glaucoma have several epidemiological and histological overlaps in pathogenesis in recent years. Appreciation of the characteristics of PET/CT and their role on Alzheimer’s disease evolves with advances of imaging technology. It is also being explored to study the pathogenesis of glaucoma and as an early diagnosis and treatment method of glaucoma, however, quite a few of questions still need to be further clarified and explored. This article mainly reviews the clinical research and application progress of positron imaging agents in glaucoma. 
  
 
</p></abstract><kwd-group><kwd>正电子发射型计算机断层显像，青光眼，视神经损害, PET/CT</kwd><kwd> Glaucoma</kwd><kwd> Optic Nerve Damage</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>近年来，人们对青光眼发病机制的了解不断加深，发现了阿尔茨海默病(AD)和青光眼在发病机制上有多种流行病学和组织学重叠。随着影像技术的不断发展，人们应用PET/CT诊断AD积累了一定的经验，用其研究青光眼的发病机制和作为青光眼的早期诊疗评估方法也在进行研究。然而，目前仍有很多问题需要明晰和探索。本文主要对此无创的影像检查在青光眼的诊疗方面的应用进展进行综述。</p></sec><sec id="s2"><title>关键词</title><p>正电子发射型计算机断层显像，青光眼，视神经损害</p></sec><sec id="s3"><title>The Application Prospect of PET/CT in the Diagnosis and Evaluation of Glaucoma<sup> </sup></title><p>Wanna Ren<sup>1</sup>, Jinrui Ma<sup>2</sup>, Yuhan Bao<sup>1</sup>, Jiangyan Liu<sup>3</sup>, Zhencun Cui<sup>3</sup></p><p><sup>1</sup>Department of Ophthalmology, The Second Affiliated Hospital of Lanzhou University, Lanzhou Gansu</p><p><sup>2</sup>Department of Ophthalmology, Gansu Rehabilitation Center Hospital, Lanzhou Gansu</p><p><sup>3</sup>Department of Nuclear Medicine, The Second Affiliated Hospital of Lanzhou University, Lanzhou Gansu</p><p><img src="//html.hanspub.org/file/6-2230310x4_hanspub.png" /></p><p>Received: Nov. 16<sup>th</sup>, 2020; accepted: Dec. 2<sup>nd</sup>, 2020; published: Dec. 9<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/6-2230310x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>With the development of understanding of the pathogenesis of glaucoma, we find that Alzheimer’s disease (AD) and glaucoma have several epidemiological and histological overlaps in pathogenesis in recent years. Appreciation of the characteristics of PET/CT and their role on Alzheimer’s disease evolves with advances of imaging technology. It is also being explored to study the pathogenesis of glaucoma and as an early diagnosis and treatment method of glaucoma, however, quite a few of questions still need to be further clarified and explored. This article mainly reviews the clinical research and application progress of positron imaging agents in glaucoma.</p><p>Keywords:PET/CT, Glaucoma, Optic Nerve Damage</p><disp-formula id="hanspub.39066-formula43"><graphic xlink:href="//html.hanspub.org/file/6-2230310x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-2230310x7_hanspub.png" /> <img src="//html.hanspub.org/file/6-2230310x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>青光眼是主要致盲眼病之一，其视神经损害的机制主要有两种学说，机械学说和缺血学说。青光眼对视力造成的不可逆损伤使人们越来越关注其早期预防、早期发现的检查手段，期待早期可控制病情发展，挽救患者视力，减轻患者经济及心理负担。随着神经影像技术的发展及学者们对青光眼神经损伤机制的研究，我们对于青光眼患者的视觉中枢结构、物质代谢、血流灌注及神经元活性等的改变情况也有了深入的了解。在神经影像检查方法中光学相干计算机断层扫描(Optical Coherence Tomography, OCT)广泛应用于临床，在对青光眼造成的视神经损伤的检查中起了重要作用，磁共振成像(Magnetic Resonance Imaging, MRI)可结合其传统扫描与弥散成像、血流灌注成像、波谱分析、功能成像等特点，为临床诊断神经损伤提供了更多的依据 [<xref ref-type="bibr" rid="hanspub.39066-ref1">1</xref>]。然而这些检查诊断视神经损伤时患者病情已经发展至进展期或中晚期，我们需要探索一种检查方法能在神经损伤之前，在脑内神经代谢出现异常时能进行更早期诊断的检查手段，这对青光眼患者将会有更巨大的意义。根据目前学者对于神经代谢及病变的关系的研究结果来看，正电子发射计算机断层显像(Positron Emission Tomography, PET)检查会是一种新的思路和方法，并有可能成为一种新型的检查手段。</p></sec><sec id="s6"><title>2. PET/CT在眼科的应用及发展现状</title><p>正电子发射断层显像/计算机断层显像(Positron Emission Tomography/Computed Tomography, PET/CT)由PET和CT两部分组成。PET是一种放射性核素显像技术，其基本原理是放射性核素的示踪作用。引入人体的放射性的特殊药物可被体内某部位选择性摄取浓聚，同时因其具有放射性，可用核仪器探测其行踪，获得其在体内分布的图像。将PET图像与CT图像融合，PET显示病变部位的病理生理特征，更容易发现病灶，CT精确定位病灶，显示病灶结构变化，两者优势互补，反映病灶的病理生理变化及形态结构。</p><p>核医学放射性核素示踪技术具有无创、安全和早期检测组织器官血流、功能代谢和受体密度等变化的独特优势，尤其是PET/CT对血流、代谢和受体的显像是目前公认的早期诊断AD的方法。目前PET/CT在眼科方面的应用主要在于脉络膜黑色素瘤、视网膜母细胞的早期诊断。如全身PET/CT用于初次分期脉络膜黑色素瘤。在眼部，<sup>18</sup>FDG-PET/CT可用于评价脉络膜黑色素瘤的坏死特征，研究显示明显的代谢性损伤，代表细胞活力不存在，排除活性黑素瘤细胞并排除其他转移灶 [<xref ref-type="bibr" rid="hanspub.39066-ref2">2</xref>]。FDG-PET检查还可用于显示双侧中央视网膜动脉闭塞引起的突发性失明症性巨细胞性动脉炎 [<xref ref-type="bibr" rid="hanspub.39066-ref3">3</xref>]。另外，在具有严重葡萄膜炎形式的QuantiFERON阳性患者中，例如匍行性脉络膜炎和闭塞性视网膜血管炎，<sup>18</sup>F-FDG-PET/CT可用于鉴定适合活检的病变，并有助于确定诊断和治疗结核病诱发的眼内炎症 [<xref ref-type="bibr" rid="hanspub.39066-ref4">4</xref>]。而PET/CT在青光眼的发病机制及诊断与评估方面的研究还处于起步阶段。</p></sec><sec id="s7"><title>3. 青光眼中的β淀粉样蛋白及其显像方式</title><sec id="s7_1"><title>3.1. β淀粉样蛋白在青光眼发病中的作用</title><p>β淀粉样蛋白(Aβ)在眼部多部位都有表达 [<xref ref-type="bibr" rid="hanspub.39066-ref5">5</xref>]，在青光眼的神经损伤方面，也起了一定的作用。Aβ是β前体样蛋白(APP)降解产物。APP是广泛存在于全身组织细胞的单次跨膜蛋白，对正常的细胞代谢有着积极地作用。APP有两条生理代谢途径，主要途径是由α-分泌酶裂解产生分泌性APP，其有一定生理作用，对细胞分化及形态改变有关，并有促神经存活、抗兴奋性氨基酸毒性作用 [<xref ref-type="bibr" rid="hanspub.39066-ref6">6</xref>]。另一条途径是经β-内分泌酶及γ-内分泌酶裂解产生Aβ。可溶性Aβ本身并不具有毒性，但经β-折叠形成丝状纤维聚集物变为不溶性沉淀后形成斑块异常聚集在细胞外则具有神经细胞毒性。Aβ可引起胆碱能神经损伤、诱导神经细胞凋亡、增加过氧化损伤及炎症反应，各种机制相互作用导致神经损伤。研究 [<xref ref-type="bibr" rid="hanspub.39066-ref7">7</xref>] 显示：APP代谢产物和Aβ40、Aβ42，由视网膜神经细胞裂解分泌后直接进入玻璃体，通过玻璃体前界膜进入房水，通过房水循环排出眼外。同时玻璃体中相对分子质量较小的Aβ也可以直接弥撒进入房水。所以，正常人的房水中可以检测到Aβ [<xref ref-type="bibr" rid="hanspub.39066-ref8">8</xref>]，而青光眼患者的房水中可以检测到高浓度的Aβ [<xref ref-type="bibr" rid="hanspub.39066-ref9">9</xref>]，Aβ可能参与青光眼的发病机制，Aβ对于青光眼视神经的损害的这项研究，对于青光眼的发病机制及早期检查评估提供了新的思路。所以，对于青光眼中Aβ的早期发现及早期检测，就显得尤为重要。Aβ作为显影的标准物，可能在青光眼的无创分子影像诊断中有一定的作用。</p></sec><sec id="s7_2"><title>3.2. β淀粉样蛋白的显像方式</title><p>正电子放射性药物可选择性与β淀粉样蛋白结合，核医学显像通过活体动态的显示病灶，客观定量地反映患者脑内淀粉样斑块的聚集水平，是诊断AD的有用且可靠的诊断工具并能对药物疗效进行评价 [<xref ref-type="bibr" rid="hanspub.39066-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.39066-ref11">11</xref>]。</p><p>β淀粉样蛋白结合类的PET显影剂的研究起源追溯到20世纪90年代中期，生物实验表明，组织学染色剂刚果红、吉姆萨、硫磺素-T能和淀粉样蛋白非特异性结合而使之染色，β淀粉样蛋白结合的PET小分子显影剂，其化学骨架主要来源于刚果红和硫磺素-T等组织染色剂，其组成包括氨基萘类、苯噻嗪类、二本烯类和咪唑吡啶四大类。</p><p>目前使用最广泛的Aβ标记PET示踪剂是11C匹兹堡化合物B (11C-PIB)，是用于阿尔茨海默病(AD)病理染色的硫黄素T的类似物，可特异性与老年痴呆病的标志性物质β淀粉样蛋白斑块结合，显示大脑内是否有β淀粉样斑块沉淀，从而诊断AD或者其认知功能障碍。11C-PIB显影剂能够迅速进入脑内并快速从脑内清除，且能和脑内的β淀粉样蛋白特异性结合，图像信噪比高，但11C半衰期较短，只有20分钟，限制了在检查中的应用 [<xref ref-type="bibr" rid="hanspub.39066-ref12">12</xref>]。</p><p>18F标记显像剂在临床应用方面更有前景，18F拥有较长的半衰期110 min，衰变产生的正电子湮没前在组织中的射程短，图像空间分辨率高，更利于临床中显像诊断追踪。</p><p>18F-AV45是一种新型放射性药物，能够选择性地结合β淀粉样蛋白A斑块。18F-AV45在体外特异性结合Aβ，是一种安全的PET示踪剂，用于研究人脑中的Aβ分布。18F-AV-45药代动力学性能更优良，显影的图像信噪比更高 [<xref ref-type="bibr" rid="hanspub.39066-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.39066-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.39066-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.39066-ref16">16</xref>]，己经完成了临床三期的试验，2012年成为美国食品药品监督管理局(FDA)批准的第一个用于阿尔茨海默病临床诊断的放射性药物 [<xref ref-type="bibr" rid="hanspub.39066-ref17">17</xref>]。</p></sec></sec><sec id="s8"><title>4. PET/CT在青光眼中的应用进展及前景</title><sec id="s8_1"><title>4.1. 青光眼与阿尔茨海默病的关系</title><p>阿尔茨海默病(Alzheimer disease, AD)是一种以认识和记忆损害为主要表现的中枢神经退行性病变，视觉损害是其最早出现的症状，包括对比敏感度、深度和运动感知的异常 [<xref ref-type="bibr" rid="hanspub.39066-ref18">18</xref>]。近年研究发现AD的神经损伤与青光眼的神经损伤可能有相同的机制，有研究显示 [<xref ref-type="bibr" rid="hanspub.39066-ref19">19</xref>]，青光眼患者的痴呆风险明显高于非青光眼患者，而AD患者正常眼压性青光眼发病率较正常高。在脑内存在Aβ淀粉样斑块是AD的病理特征，淀粉样斑块在脑内的增加具有神经毒性并导致进一步的病理损害，包括神经元纤维的缠结，突触的缺失及功能障碍，神经退行性改变，这样的病理损害也同样存在在青光眼患者中。AD和青光眼存在着相似的疾病特征，包括细胞外Aβ蛋白、tau蛋白过度磷酸化的沉积、神经炎症和神经胶质细胞过度活跃。这些因素都会造成神经损伤，从而导致AD患者认知障碍以及青光眼患者视功能损害 [<xref ref-type="bibr" rid="hanspub.39066-ref20">20</xref>]。</p></sec><sec id="s8_2"><title>4.2. PET/CT与青光眼的早期诊断与评估</title><p>PET通过放射性显像示踪剂探测β淀粉样蛋白斑块，对AD的早期诊断具有重要意义，Aβ PET显像可以用于AD临床早期诊断、与其他认知障碍疾病的鉴别诊断以及Aβ靶向治疗药物受试者的选择及疗效评估等 [<xref ref-type="bibr" rid="hanspub.39066-ref21">21</xref>]。该技术目前已比较成熟，已广泛应用于临床。而根据青光眼与AD的密切关系，以及青光眼与AD神经损伤方面存在的相同机制，可考虑将PET/CT在AD中的诊断方法运用到青光眼的早期诊断及病情评估上。而最新的一项研究将<sup>11</sup>C-PIB PET/CT应用于测量AD患者神经纤维层厚度，发现与健康对照组相比，<sup>11</sup>C-PIB PET/CT阳性患者的眼R NFL和GCL明显变薄，IPL和外核层也表现出明显的变薄，证明RNFL和GCL对于AD的早期诊断具有潜在的筛查价值 [<xref ref-type="bibr" rid="hanspub.39066-ref22">22</xref>]。通过运用其对神经损伤进行早期诊断，检测视网膜纤维层内Aβ的量的情况以及视神经损伤情况，并对能够降低淀粉样蛋白水平的药物效力进行评价。有学者指出，青光眼视神经的损害是全视路的，不只局限在视网膜，还在于视神经，视交叉、视束、外侧膝状体、视放射及枕叶视皮层在内的整个视路 [<xref ref-type="bibr" rid="hanspub.39066-ref1">1</xref>]，目前Masamitsu Shimazawa [<xref ref-type="bibr" rid="hanspub.39066-ref23">23</xref>] 用PET对实验性青光眼猴的外侧膝状体lateral geniculate nucleus (LGN)变性进行了检查，结果提示高眼压青光眼猴中PET显像可以检测到LGN的变性。用PET去检测某种标记物，作为青光眼可能的诊断指标，可能在青光眼的无创分子影像诊断中有用。</p></sec><sec id="s8_3"><title>4.3. PET/CT在青光眼诊疗中的应用与研究展望</title><p>通过对AD与青光眼相同神经代谢改变及检测手段的研究，将更敏感的影像学检查方法应用到青光眼检查，使得青光眼的早期发现和诊断有更多可能，对于有青光眼家族史或者有早期眼部胀痛不适、视力下降、眼压升高病史的患者，可以在青光眼临床病变的更早阶段发现神经代谢方面的异常，在形成视神经损伤之前进行干预，控制病情发展。此外，PET可选择性的示踪，可选择性的将药物与病变部位特异性结合，也为有病变的部位的进一步治疗提供新的方法。然而，目前各方面的研究还处于早期阶段，还有一些限制性问题需要解决，如：Aβ显像显示的脑内Aβ负荷状态与PET显示的代谢改变(如部位或程度)相关性如何?显像剂显示脑内的Aβ负荷状态与青光眼临床发病的关系究竟如何?其参数有什么规律?这些都有待进一步的研究。</p><p>对于青光眼究竟是局部的眼病还是中枢系统疾病，一些学者一直有所争议。通过PET的显影，可以从功能代谢方面更全面的了解青光眼视神经与颅神经及脑部的关系，这种无创的检查方法、检查结果，对于我们了解青光眼的发病机制提供了一种新思路，也为青光眼的诊断评估和治疗提供了一种新方法。</p><p>综上所述，PET/CT在青光眼诊疗方面的应用尚处于探索与研究阶段，这种无创快速的检查方法不仅能对我们认识和了解青光眼的发病机制提供更多依据，同时也能为其他疾病的检查和诊断提供新的思路和方法，促进新的有效地诊疗技术的发展。</p></sec></sec><sec id="s9"><title>基金项目</title><p>甘肃省自然科学基金资助(编号：18JR3RA314)。</p></sec><sec id="s10"><title>文章引用</title><p>任婉娜,马金瑞,包宇涵,柳江燕,崔振存. PET/CT影像新技术在青光眼诊断与评估方面的研究进展The Application Prospect of PET/CT in the Diagnosis and Evaluation of Glaucoma[J]. 眼科学, 2020, 09(04): 274-279. https://doi.org/10.12677/HJO.2020.94039</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39066-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">张绍丹, 卿国平, 王怀洲, 等. 神经影像学技术在认识青光眼相关的中枢损伤性疾病过程中的作用[J]. 中华眼科医学杂志: 电子版, 2016, 6(2): 93-96.</mixed-citation></ref><ref id="hanspub.39066-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Romero-Aroca, P., Montero-Jaime, M., Intriago, B., et al. (2012) 18FDG-PET/CT Assessing the Absence of Cell Viability and Excluding Metastatic Disease in a Case of Necrotic Choroidal Melanoma. European Journal of Ophthalmology, 22, 288. https://doi.org/10.5301/ejo.5000016</mixed-citation></ref><ref id="hanspub.39066-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Dietemann, S., Noblet, V., et al. (2015) FDG PET Findings of the Brain in Sudden Blindness Caused by Bilateral Central Retinal Artery Occlusion Revealing Giant Cell Arteritis. Clinical Nuclear Medicine, 40, 45-46.  
https://doi.org/10.1097/RLU.0000000000000598</mixed-citation></ref><ref id="hanspub.39066-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Deshka, D., Christoph, D., Juergen, H., et al. (2011) The Use of Positron Emission Tomography/CT in the Diagnosis of Tuberculosis-Associated Uveitis. The British Journal of Ophthalmology, 95, 1290-1294.  
https://doi.org/10.1136/bjo.2010.182659</mixed-citation></ref><ref id="hanspub.39066-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">董志章, 李娟, 孙雪荣, 等. TgAPPswePS1转基因鼠视网膜的功能损伤和Aβ斑块沉积[J]. 中华眼视光学与视觉科学杂志, 2018, 20(1): 46-52.</mixed-citation></ref><ref id="hanspub.39066-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tsuruma, K., Tanaka, Y., Shimazawa, M., et al. (2010) Induction of Amyloid Precursor Protein by the Neurotoxic Peptide, Amyloid-Beta 25-35, Causes Retinal Ganglion Cell Death. Journal of Neurochemistry, 113, 1545-1554.  
https://doi.org/10.1111/j.1471-4159.2010.06724.x</mixed-citation></ref><ref id="hanspub.39066-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Prakasam, A., Muthuswamy, A., Ablonczy, Z., et al. (2010) Differential Accumulation of Secreted AβPP Metabolites in Ocular Fluids. Journal of Alzheimer’s Disease, 20, 1243-1253. https://doi.org/10.3233/JAD-2010-100210</mixed-citation></ref><ref id="hanspub.39066-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">卢艳, 李臻, 吴越, 张健, 等. 116例正常人房水中阿尔茨海默病生物标志物与年龄相关性研究[J]. 首都医科大学学报, 2017, 38(3): 461-464.</mixed-citation></ref><ref id="hanspub.39066-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">周金子, 鲁建华, 张文芳. 青光眼患者房水中β淀粉样蛋白的检测[J]. 临床眼科杂志, 2005, 13(3): 202-204.</mixed-citation></ref><ref id="hanspub.39066-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rabinovici, G.D., Gatsonis, C., Apgar, C., et al. (2019) Association of Amyloid Positron Emission Tomography with Subsequent Change in Clinical Management among Medicare Beneficiaries with Mild Cognitive Impairment or Dementia. JAMA, 321, 1286-1294. https://doi.org/10.1001/jama.2019.2000</mixed-citation></ref><ref id="hanspub.39066-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ciarmiello, A., Tartaglione, A., Giovannini, E., et al. (2019) Amyloid Burden Identifies Neuropsychological Phenotypes at Increased Risk of Progression to Alzheimer’s Disease in Mild Cognitive Impairment Patients. European Journal of Nuclear Medicine and Molecular Imaging, 46, 288-296. https://doi.org/10.1007/s00259-018-4149-2</mixed-citation></ref><ref id="hanspub.39066-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Hatashita, S., Yamasaki, H., Suzuki, Y., et al. (2014) 18F-Flutemetamol Amyloid-Beta PET Imaging Compared with 11C-PIB across the Spectrum of Alzheimer’s Disease. European Journal of Nuclear Medicine &amp; Molecular Imaging, 41, 290-300. https://doi.org/10.1007/s00259-013-2564-y</mixed-citation></ref><ref id="hanspub.39066-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">任树华, 黄琪, 胡静超, 等. 18F-AV45 PET显像在轻微认知下降和轻度认知障碍患者中的应用[J]. 中华核医学与分子影像杂志, 2020, 40(4): 196-200.</mixed-citation></ref><ref id="hanspub.39066-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">张晨鹏, 王成, 辛玫, 等. 18F-AV45 PET/CT显像视觉分析及SUVR对不同认知障碍患者的辅助诊断价值[J]. 中华核医学与分子影像杂志, 2020, 40(4): 201-206.</mixed-citation></ref><ref id="hanspub.39066-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Jia, L., Quan, M., Fu, Y., et al. (2020) Dementia in China: Epidemiology, Clinical Management, and Research Advances. The Lancet Neurology, 19, 81-92. https://doi.org/10.1016/S1474-4422(19)30290-X</mixed-citation></ref><ref id="hanspub.39066-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lin, K.J., Haiao, I.T., Hsu, J.L., et al. (2016) Imaging Characteristic of Dual-Phase 18F-Florbetapir (AV-45/Amyvid) PET for the Concomitant Detection of Perfusion Deficits and Beta-Amyloid Deposition in Alzheimer’s Disease and Mild Cognitive Impairment. European Journal of Nuclear Medicine and Molecular Imaging, 43, 1304-1314.  
https://doi.org/10.1007/s00259-016-3359-8</mixed-citation></ref><ref id="hanspub.39066-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">D’Estanque, E., Chambert, B., Moranne, O., et al. (2016) 18F-Florbetaben: A New Tool for Amyloidosis Staging. Clinical Nuclear Medicine, 42, 50. https://doi.org/10.1097/RLU.0000000000001434</mixed-citation></ref><ref id="hanspub.39066-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Neiberg, M.N. (2009) Alzheimer’s Disease and the Eye. Eye Care Review.</mixed-citation></ref><ref id="hanspub.39066-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Tamura, H., Kawakami, H., Kanamoto, T., et al. (2006) High Frequency of Open-Angle Glaucoma in Japanese Patients with Alzheimer’s Disease. Journal of the Neurological Sciences, 246, 79-83.  
https://doi.org/10.1016/j.jns.2006.02.009</mixed-citation></ref><ref id="hanspub.39066-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sivak, J.M. (2013) The Aging Eye: Common Degenerative Mechanisms between the Alzheimer’s Brain and Retinal Disease. Investigative Ophthalmology &amp; Visual Science, 54, 871-880. https://doi.org/10.1167/iovs.12-10827</mixed-citation></ref><ref id="hanspub.39066-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Sevigny, J., Chiao, P., Bussière, T., et al. (2016) The Antibody Aducanumab Reduces Aβ Plaques in Alzheimer’s Disease. Nature, 537, 50-56. https://doi.org/10.1038/nature19323</mixed-citation></ref><ref id="hanspub.39066-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">López-de-Eguileta, A., Lage, C., López-García, S., et al. (2019) Ganglion Cell Layer Thinning in Prodromal Alzheimer’s Disease Defined by Amyloid PET. Alzheimer’s Dement, 5, 570-578. https://doi.org/10.1016/j.trci.2019.08.008</mixed-citation></ref><ref id="hanspub.39066-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Shimazawa, M., Ito, Y., Inokuchi, Y., et al. (2012) An Alteration in the Lateral Geniculate Nucleus of Experimental Glaucoma Monkeys: In Vivo Positron Emission Tomography Imaging of Glial Activation. PLoS ONE, 7, e30526.  
https://doi.org/10.1371/journal.pone.0030526</mixed-citation></ref></ref-list></back></article>